Randox – Drugs of Abuse
Throughout November our aim is to highlight how the Randox product range can be utilised to allow for the most accurate analysis of drugs of abuse, with a particular focus placed with the Evidence MultiSTAT, a fast, fully automated and versatile immunoanalyser that enables on-site detection of up to 21 drugs of abuse from a single sample of oral fluid, urine or blood.
The abuse of drugs is a growing problem worldwide and represents a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
Randox have reacted to this growing concern and are now a world leader in the drugs of abuse testing field. Our product range currently comprises classical, prescription and synthetic drugs.
The Evidence MultiSTAT offers a simple drug screening solution to those who have little or no knowledge of laboratory procedures. As an extremely versatile, desktop analyser it is ideally suited to a variety of settings including both the clinical laboratory and the emergency room.
The Evidence MultiSTAT utilises Randox’s revolutionary Biochip Array Technology to enable on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single patient sample. The MultiSTAT has the ability to run samples of whole blood, urine and oral fluid with a 2 step process from sample entry to results with the first result coming through after 17 minutes. The MultiSTAT offers an extensive test menu and requires no laboratory experience with it’s simple process of providing rapid screening and reliable results.
RX series Toxicology Testing
Renowned for quality and reliability the RX series range of clinical chemistry analysers boasts a world leading test menu comprising both therapeutic drugs and drugs of abuse. Our toxicology range comprises amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, ecstasy, EDDP, ethanol, methadone and opiates. The RX series range of clinical chemistry analysers ensures a high degree of accuracy with a wide range of testing throughputs to suit all laboratories big or small.
Reagents Drugs of Abuse Assays
In order to assist in dealing with the ongoing burden of substance abuse, Randox Reagents offer a comprehensive range of 10 assays to test for some of the top commonly abused substances including, alcohol, methamphetamine’s, cocaine, methadone, cannabis, benzodiazepines, barbiturates, EDDP, ecstasy and opiates. The Randox drugs of abuse reagents are liquid ready-to-use for increased efficiency with applications available for over 30 different analysers.
RIQAS Urine Toxicology Programme
Designed to monitor the performance of 20 drugs of abuse tests in urine, our RIQAS urine toxicology EQA program is suitable for both qualitative and quantitative methods of analysis. As the largest EQA scheme in the world, access to large peer groups is guaranteed. Additional benefits include; monthly analysis, user-friendly reports allowing at-a-glance performance assessment, ability to register up to five instruments per programme and cost savings via our unrivalled consolidation.
Throughout the month of October our aim is to highlight how the Randox clinical product range can be used to allow for the most accurate diagnosis and monitoring of cholesterol. As October is national cholesterol month, we want to raise awareness of the many dangers associated with cholesterol to better assess the risk of related complications.
Cholesterol plays a major role in atherosclerosis, the leading cause of cardiovascular disease (CVD). CVD is the leading global cause of death; accounting for over 17.9 million deaths in 2016. This figure is expected to grow to more than 23.6 million by 2030 despite the treatment of individuals with high LDL Cholesterol with statins. These statistics emphasise the urgent need for additional risk factors to be considered beyond traditional LDL Cholesterol measurement.
As a world leader in the field of cardiac risk and lipid testing, Randox are tackling the need for better cholesterol testing with our wide range of niche and high-performance assays including sdLDL Cholesterol, Lipoprotein (a) and HDL3 Cholesterol. In fact Randox is responsible for more than 15% of all cholesterol tests carried out across the globe. Read on to find out more about our complete range of clinical solutions.
Typically HDL Cholesterol, LDL Cholesterol and Triglycerides are measured to asses coronary heart disease (CAD) risk however these current methods only detect around 20% of all CAD patients. Recognising the need for more comprehensive risk assessment, the Randox range comprises sdLDL Cholesterol (sdLDL-C), HDL3 Cholesterol and Lipoprotein (a) amongst others. sdLDL-C is a vital risk marker for Myocardial Infarction (MI), research indicates that individuals with a predominance of sdLDL-C have 3-fold increased risk of MI. HDL3 Cholesterol on the other hand is widely accepted to have an inverse relationship with CVD risk, individuals with higher HDL3 Cholesterol levels are therefore at lower risk of developing CVD. Finally Lipoprotein (a) is an independent genetic risk factor for CVD with elevated levels often seen in patients with an otherwise normal lipid profile. Our complete range comprises 113 third party diagnostic reagents, applications are available for a variety of biochemistry analysers. To find out more about our cardiac risk assays click here.
Renowned for quality and reliability the RX series range of clinical chemistry analysers boasts a world leading test menu comprising both routine and novel lipid tests for accurate & reliable CVD risk assessment. In addition to novel assays such HDL3 Cholesterol, sdLDL Cholesterol, Lipoprotein (a) and Apolipoproteins, the RX series offers superior methodology for the accurate measurement of routine assays including HDL Cholesterol and LDL Cholesterol. Our superior direct clearance method for HDL cholesterol ensures a high degree of accuracy even with abnormal samples containing elevated levels of triglycerides. Similarly no sample pre-treatment is required with our direct clearance method for LDL Cholesterol resulting in less variability and excellent correlation to ultracentrifugation methods. To view the complete RX series test menu and discover more on our testing solutions click here.
Internal Quality Control
The Acusera Lipid controls offer testing for the complete lipid profile, including HDL, LDL and Total Cholesterol. Available in either liquid ready-to-use or lyophilised formats, our controls are ideal for laboratories of any size with flexible options available for each control. Our lipid controls are manufactured from 100% human serum, ensuring commutability, and therefore mimic the performance of a patient sample.
External Quality Assessment
Designed to monitor the performance of up to 7 lipid parameters, the RIQAS Lipid EQA programme is manufactured from 100% human serum ensuring commutability. With access to large peer groups and user-friendly reports supplied, RIQAS is the EQA scheme for your laboratory. Frequent reporting and flexible programme options are only two of many benefits associated with the RIQAS Lipid Programme.
Randox are dedicated to improving health worldwide. Throughout the month of September we hope to highlight how the Randox clinical product range can assess the impact of infection through swift diagnosis, allowing the necessary steps to be taken in order to improve an individual’s health. Infection is the infiltration of an organism’s bodily tissues by disease-causing agents, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. The Randox portfolio comprises a wide range of products to assess the impact of infection. The RX series dedicated testing panel comprises of IgA, hsCRP and ASO which are also available for third-party use. The extensive QC range caters for assessment of infectious disease testing in both liquid & lyophilised formats.
The Randox range of third-party reagents enables the clinical analysis of 113 different analytes with comprehensive range measurements and excellent correlations to reference methods. Applications are available detailing instrument-specific settings for a variety of biochemistry analysers. Randox offer several assays for the detection of infection.
IgG (the most abundant antibody) and IgM (the first antibody made in response to infection) can be used in the diagnosis of Dengue Fever. More than 40% of the global population, in more than 100 countries are at risk of the Dengue Virus (WHO). IgA is an antibody that lines the mucous membranes lining the mouth, airways, and digestive tract. A deficiency in IgA is common in patients with bronchitis, conjunctivitis and otitis media. Other Randox assays that may be used detect differing infections include: albumin, ferritin, alpha-1-antitrypsin (AAT), complement C3, complement C4, haptoglobin, CRP, alpha-1-acid glycoprotein (AGP) and anti-streptolysin (ASO).
The RX series range of Clinical Chemistry Analysers offer the most comprehensive testing profile for assessing inflammation and infection complications which identifies any potential infectious issues a patient may have. The world famed RX series test menu includes specific tests associated with inflammation and infection including Alpha-I Acid Glycoprotein, ASO, CRP, Lactate and Rheumatoid Factor tests.
The RX series zinc test will assess the levels of zinc in a patient sample, zinc plays a significant role in an individual’s health. It’s functions include cell and enzyme production as well as wound healing, therefore it is vitally important for a patient to be aware if they are either deficient or within the normal range for zinc and other infectious related tests to ensure potential infections can be prevented. To view the full RX series test menu click here.
Internal Quality Control
Randox has partnered up with Qnostics to provide a wide range of molecular controls for infectious disease testing. Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.
External Quality Assessment
Randox have also partnered up with QCMD to offer a vast array of molecular EQA programmes for infectious disease testing. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics. Frequent challenges, comprehensive reports and international accreditation ensures the best assessment of test system performance.